A phase I study to evaluate the safety and immunogenicity of ALVAC-HIV vCP1521 [HIV vaccine vCP1521] in infants born to HIV-1 infected women in Uganda.

Trial Profile

A phase I study to evaluate the safety and immunogenicity of ALVAC-HIV vCP1521 [HIV vaccine vCP1521] in infants born to HIV-1 infected women in Uganda.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Oct 2013

At a glance

  • Drugs HIV vaccine vCP1521 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Oct 2013 Results published in JAIDS.
    • 03 May 2012 Actual patient number is 60 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top